{"url_path":"/sec/pyxs/8-k/2026-06-15/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1782223/0001193125-26-271137-index.html","accession_number":"0001193125-26-271137","cik":"0001782223","ticker":"PYXS","issuer_name":"Pyxis Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1782223/0001193125-26-271137-index.html","primary_entity_key":"0001782223","primary_entity_name":"Pyxis Oncology, Inc."},"word_count":316,"has_tables":true,"body_markdown":"## Item 5.07. Submission of Matters to a Vote of Security Holders.\n\nOn June 15, 2026, Pyxis Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders at 10:00 a.m. Eastern Daylight Time in a virtual format via live audio webcast (the “Annual Meeting”). As of April 20, 2026, the Company’s record date, there were a total of 62,855,464 shares of common stock outstanding and entitled to vote at the Annual Meeting. At the beginning of the Annual Meeting, 47,302,035 shares of common stock were present virtually, in person or by proxy, and, therefore, a quorum was present. Two items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.\n\n \n\nProposal One: Election of Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger as Class II Directors\n\n \n\nMr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger were elected to serve as Class II directors to hold office until the Company’s 2029 Annual Meeting of Stockholders and until the election and qualification of their successors. Votes were cast as follows:\n\n \n\nName of Director Nominee\n\nFor\n\nWithheld\n\nBroker Non-Votes\n\nMr. Thomas Civik\n\n27,341,415\n\n1,981,857\n\n17,978,763\n\nDr. Freda Lewis-Hall, M.D.\n\n \n\n19,188,755\n\n \n\n10,134,517\n\n \n\n17,978,763\n\nMr. Michael A. Metzger\n\n \n\n26,521,575\n\n \n\n2,801,697\n\n \n\n17,978,763\n\n \n\n \n\nProposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm\n\n \n\nThe stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following vote:\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n46,203,257\n\n \n\n1,076,997\n\n \n\n21,781\n\n \n\n                     —\n\n \n\n##  \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nPyxis Oncology, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 15, 2026\n\nBy:\n\n/s/ Jitendra Wadhane\n\n \n\n \n\n \n\nJitendra Wadhane\nPrincipal Financial and Accounting Officer"}